-
1.发明公开
公开(公告)号：EP3092006A2
公开(公告)日：2016-11-16
申请号：EP15735468.9
申请日：2015-01-08
IPC分类号： A61K39/395 , A61K39/00 , A61K38/00 , C07K16/00
CPC分类号： C07K16/2803 , A61K38/1709 , A61K38/177 , A61K39/395 , A61K47/6803 , A61K47/6857 , A61K47/6869 , A61K2039/505 , A61K2039/507 , C07K16/2842 , C07K16/2896 , C07K16/3023 , C07K2317/33 , C07K2317/76 , A61K2300/00
摘要： Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy, which optionally includes an agent that selectively blocks CD47 binding to SIRPα.
摘要翻译： 提供了用于治疗肺癌，特别是具有靶向治疗的小细胞肺癌的方法，其任选地包括选择性阻断CD47与SIRPα结合的药剂。
-
公开(公告)号：EP3056515A1
公开(公告)日：2016-08-17
申请号：EP16160476.4
申请日：2009-01-15
CPC分类号： C07K16/2803 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C12N5/0093 , C12N5/0694 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , G01N33/5011 , G01N33/57426 , G01N2500/04
摘要： Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
摘要翻译： 提供了用于操纵细胞（包括造血细胞，例如细胞）的吞噬作用的方法。 循环造血细胞，骨髓细胞等; 和实体瘤细胞。 在本发明的一些实施方案中，循环细胞是造血干细胞或造血祖细胞，特别是在需要防止吞噬作用的移植背景下。 在其他实施方案中，循环细胞是白血病细胞，特别是急性骨髓性白血病（AML），其中需要增加吞噬作用。
-
公开(公告)号：EP2242512B1
公开(公告)日：2016-04-27
申请号：EP09701993.9
申请日：2009-01-15
IPC分类号： C07K16/28 , A61K39/395 , C07K16/46 , A61K39/00 , C07K16/18
CPC分类号： C07K16/2803 , A61K39/39558 , A61K47/6851 , A61K47/6861 , A61K47/6863 , A61K47/6865 , A61K47/6867 , A61K47/6869 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2896 , C07K16/30 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/31 , C07K2317/73 , C07K2317/76
摘要： Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
摘要翻译： 提供了用于操纵癌细胞吞噬作用的方法，包括例如。 白血病，包括癌的实体瘤等
-
公开(公告)号：EP2242512A1
公开(公告)日：2010-10-27
申请号：EP09701993.9
申请日：2009-01-15
IPC分类号： A61K39/395 , C07K16/46
CPC分类号： C07K16/2803 , A61K39/39558 , A61K47/6851 , A61K47/6861 , A61K47/6863 , A61K47/6865 , A61K47/6867 , A61K47/6869 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2896 , C07K16/30 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/31 , C07K2317/73 , C07K2317/76
摘要： Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
-
公开(公告)号：EP3553087A1
公开(公告)日：2019-10-16
申请号：EP19163809.7
申请日：2015-01-08
IPC分类号： C07K16/28 , A61K39/395 , A61K38/17 , A61P35/00
摘要： Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy. The therapy is targeted at one or more cell-surface antigens, including CD24, CD166, CD56, CD326, CD298, CD29, CD63, CD9, CD164, CD99, CD46, CD59, CD57, CD165, and EpCAM, which optionally includes an agent that selectively blocks CD47 binding to SIRPa.
-
6.发明公开MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS 审中-公开MARKERFÜRSTAMMZELLEN VON AKUTER MYELOISCHERLEUKÄMIE
公开(公告)号：EP3043181A1
公开(公告)日：2016-07-13
申请号：EP15198767.4
申请日：2009-01-13
摘要： Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
摘要翻译： 鉴定急性骨髓性白血病干细胞（AMLSC）的标志物。 标记与正常对照细胞相比差异表达，可用作诊断和治疗靶点。
-
公开(公告)号：EP1194035B1
公开(公告)日：2007-09-19
申请号：EP00946928.9
申请日：2000-06-29
发明人： WEISSMAN, Irving, L. , TRAVER, David, Jeffrey , AKASHI, Koichi Dept,of Cancer,Immunology & AIDS
CPC分类号： C12Q1/6881 , C12N5/0647 , C12N2501/125 , C12N2501/14 , C12N2501/145 , C12N2501/22 , C12N2501/23 , C12N2501/26 , C12N2503/00 , C12Q2600/158
摘要： A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor α); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.
-
8.发明公开PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF BETA-CATENIN SIGNALING PATHWAYS 审中-公开干细胞对CYTOTOXISCHESUBSTANZEN由β-连环蛋白的调控信号LEAD双向保护
公开(公告)号：EP1567008A2
公开(公告)日：2005-08-31
申请号：EP03790355.6
申请日：2003-12-05
CPC分类号： A61K31/513 , A61K31/522 , A61K31/525 , A61K31/7072 , A61K31/7076 , C12N5/0647 , C12N2501/415 , C12Q1/6881 , C12Q1/6883 , C12Q2600/156
摘要： Reagents that block the extracellular activation of β-catenin are used to induce quiescence in normal stem cells, in order to reduce the killing of stem cells by anti-proliferative agents.
-
9.发明公开
公开(公告)号：EP1536688A2
公开(公告)日：2005-06-08
申请号：EP03754548.0
申请日：2003-09-12
CPC分类号： C12N5/0644 , C12N2503/02
摘要： A substantially enriched mammalian hematopoietic cell population is provided, which is characterized as a progenitor cell committed to the megakaryocyte lineage. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD9 and CD41, in conjunction with other markers expressed on lineage committed progenitor cells. These cells give rise exclusively to megakaryocytes and platelets, as evidenced by their growth and differentiation in vitro and in vivo.
摘要翻译： 提供基本上富集的哺乳动物造血细胞群体，其特征在于作为祖细胞定向于巨核细胞谱系。 提供了分离和培养这些细胞的方法。 细胞富集方法使用特异性识别CD9和CD41的试剂以及在谱系定型祖细胞上表达的其他标志物。 这些细胞仅产生巨核细胞和血小板，如其体外和体内生长和分化所证明的。
-
公开(公告)号：EP3448421A1
公开(公告)日：2019-03-06
申请号：EP17790649.2
申请日：2017-05-01
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.028 秒)
